Form 4: LENZ Therapeutics Director Receives Stock Option Grant

Director Kimberlee C. Drapkin was granted 22,100 stock options in LENZ Therapeutics, Inc. as part of standard compensation.

Summary

• Director Kimberlee C. Drapkin received a grant of 22,100 stock options on June 15, 2026.
• The options have an exercise price of $6.63 per share.
• The options are set to vest in full on the earlier of June 15, 2027, or the date of the next annual meeting of stockholders, contingent on continued service as an Outside Director.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is subject to market volatility and the future performance of LENZ common stock.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to non-executive directors are standard practice in the biotechnology sector to attract and retain board talent, aligning director incentives with long-term corporate milestones.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard corporate governance practices for publicly traded biotech companies.
• The vesting schedule of one year is typical for annual director equity awards.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of options on June 15, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

LENZ Therapeutics, Form 4, Insider Trading, Stock Options, Director Compensation, Biotech